{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:42Z","timestamp":1791993942686,"version":"4.4.0"},"reference-count":34,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s475744","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:35:36Z","timestamp":1726187736000},"page":"641-652","source":"Crossref","is-referenced-by-count":1,"title":["Experts\u2019 Opinion in Fabry Disease Management and the Unmet Medical Need: The Saudi Perspective"],"prefix":"10.2147","volume":"Volume 20","author":[{"given":"Majid","family":"Alfadhel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouriya","family":"Al Sannaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawda","family":"Sunbul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Al-Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumayah","family":"Askandarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Alanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoun","family":"Elawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9056-1546","authenticated-orcid":true,"given":"Konstantinos","family":"Fourtounas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2147\/JMDH.S290580","volume":"15","author":"Paim-Marques","year":"2022","journal-title":"J Multidiscip Healthc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.15537\/smj.2020.8.25184","volume":"41","author":"Alhemyadi","year":"2020","journal-title":"Saudi Med J"},{"key":"ref4","first-page":"389","volume":"11","author":"Ezzat","year":"2021","journal-title":"Am J Med Med Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5582\/irdr.2021.01132","volume":"11","author":"\u015anit","year":"2022","journal-title":"Intractable Rare Dis Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"Van Der Tol","year":"2014","journal-title":"J Med Genet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2147\/TCRM.S247814","volume":"16","author":"Vardarli","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","volume":"55","author":"Doheny","year":"2018","journal-title":"J Med Genet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.30574\/gscbps.2021.14.1.0018","volume":"14","author":"Aziz","year":"2021","journal-title":"GSC Biol Pharm Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/jmd2.12156","volume":"56","author":"Nampoothiri","year":"2020","journal-title":"JIMD Rep"},{"key":"ref12","doi-asserted-by":"publisher","volume-title":"JIMD Reports","year":"2017","DOI":"10.1007\/8904_2017_21"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ymgme.2020.04.006","volume":"130","author":"Stiles","year":"2020","journal-title":"Mol Genet Metab"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ymgme.2019.03.010","volume":"127","author":"Ramaswami","year":"2019","journal-title":"Mol Genet Metab"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/biom12101460","volume":"12","author":"Amodio","year":"2022","journal-title":"Biomolecules"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/cge.13694","volume":"97","author":"Balendran","year":"2020","journal-title":"Clin Genet"},{"key":"ref18","unstructured":"Stewart J. Elfabrio FDA approval history. Available from: https:\/\/www.drugs.com\/history\/elfabrio.html. Accessed November 14, 2023"},{"key":"ref19","unstructured":"Elfabrio. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elfabrio. Accessed November 14, 2023."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/jimd.12228","volume":"43","author":"Van Der Veen","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/ph16020320","volume":"16","author":"Umer","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","volume":"96","author":"Germain","year":"2019","journal-title":"Clin Genet"},{"key":"ref23","unstructured":"FDA approves enzyme replacement therapy pegunigalsidase alfa for Fabry disease. Available from: https:\/\/www.neurologylive.com\/view\/fda-approves-enzyme-replacement-therapy-pegunigalsidase-alfa-for-Fabry. Accessed June 19, 2023."},{"key":"ref24","volume-title":"Enzyme-Replacement Therapies for Lysosomal Storage Diseases","year":"2013"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e035182","DOI":"10.1136\/bmjopen-2019-035182","volume":"10","author":"Hughes","year":"2020","journal-title":"BMJ Open"},{"key":"ref27","unstructured":"SmPC\u202f: summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fabrazyme-epar-product-information_en.pdf. Accessed June 19, 2023."},{"key":"ref28","unstructured":"Highlights of Prescribing Information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103979s5309lbl.pdf. Accessed January 9, 2024."},{"key":"ref29","unstructured":"SmPC: replagal. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/replagal-epar-product-information_en.pdf. Accessed August 30, 2024."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.omtm.2022.10.007","volume":"27","author":"van der Veen","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e20180002","DOI":"10.1590\/2326-4594-jiems-2018-0002","volume":"7","author":"Brunelli","year":"2019","journal-title":"J Inborn Errors Metab Screen"},{"key":"ref32","unstructured":"Alfadhel M, Moubayed H. Monitoring the response to enzyme replacement therapy. In: Protocol for lysosomal diseases patients started on enzyme replacement therapy. Riyadh Saudi Arabia: King Fahd National Library: 2016:94."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ckj\/sfw082","volume":"9","author":"Mignani","year":"2016","journal-title":"Clin Kidney J"}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/95648","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/95648","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:35:42Z","timestamp":1726187742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/experts-opinion-in-fabry-disease-management-and-the-unmet-medical-need-peer-reviewed-fulltext-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s475744","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}